Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 27;18(1):e0279027.
doi: 10.1371/journal.pone.0279027. eCollection 2023.

Reducing Vaccinia virus transmission indoors within 60 seconds: Applying SAFEAIR-X aerosol with Iodine-V as a disinfectant

Zoltán Köntös  1
Affiliations

Reducing Vaccinia virus transmission indoors within 60 seconds: Applying SAFEAIR-X aerosol with Iodine-V as a disinfectant

Zoltán Köntös. PLoS One. .

Abstract

Iodine-V ((C26H39N4O15)x * (I2)y) demonstrates an in vitro virucidal activity by deactivating SARS-CoV-2 viral titers. It combines elemental iodine (I2) and fulvic acid (C14H12O8), forming a clathrate compound. The antiviral properties of Iodine-V reduce viral load in the air to inhibit viral transmission indoors. This antiviral property was applied to form a disinfectant solution called SAFEAIR-X Aerosol. The current study evaluates the antiviral efficacy of Iodine-V in aerosol form in a prototype called SAFEAIR-X Aerosol. The experiment measured the antiviral efficacy of SAFEAIR-X following exposure to the Vaccinia virus (VACV) samples as a confirmed surrogate for SARS-CoV-2. The SAFEAIR-X showed 96% effectiveness, with 2 seconds of spraying duration and 60 seconds of contact time releasing less than 0.0001 ppm of iodine into the air, and a log reduction value of 1.50 at 60 seconds in 2 out of 3 tests was observed. Therefore, this study demonstrates SAFEAIR-X aerosol as a potential indoor surface and air disinfectant.

PubMed Disclaimer

Conflict of interest statement

The author has read the journal’s policy and the author of this manuscript has the following competing interests: KZ is a paid employee of IOI Investment Zrt, the manufacturing company of Iodine-V. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents associated with this research to declare.

References

    1. Dietz L, Horve PF, Coil DA, Fretz M, Eisen JA, Van Den Wymelenberg K. 2019 novel coronavirus (COVID-19) pandemic: built environment considerations to reduce transmission. mSystems. 2020;5: e00245–20. doi: 10.1128/mSystems.00245-20 - DOI - PMC - PubMed
    1. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. Environ Res. 2020;188: 109819. doi: 10.1016/j.envres.2020.109819 - DOI - PMC - PubMed
    1. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021;174: 69–79. doi: 10.7326/M20-5008 - DOI - PMC - PubMed
    1. National Center for Immunization and Respiratory Diseases (NCIRD). COVID-19 science briefs. In: Scientific brief: SARS-CoV-2 transmission. Atlanta (GA): Centers for Disease Control and Prevention (US); 2021. - PubMed
    1. Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol. 2021;19: 528–545. doi: 10.1038/s41579-021-00535-6 - DOI - PMC - PubMed

Publication types